Supplementary Figure S3 from Phase II Trial of Ponatinib in Patients with Metastatic Gastrointestinal Stromal Tumor following Failure or Intolerance of Prior Therapy with Imatinib (POETIG Trial)

October 1, 2025Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

Ponatinib shows promise in treating metastatic gastrointestinal stromal tumor after imatinib failure, with improved outcomes for T670I-mutant KIT patients.
The treatment exhibited efficacy in patients experiencing intolerance to prior therapies, highlighting its potential role in challenging cases.
Structural analyses reveal interactions of sunitinib, regorafenib, and ripretinib with T670I-mutant KIT, offering insights into drug mechanisms.
The phase II trial findings emphasize the need for ongoing investigation into novel therapies for resistant tumor mutations.

We only have this paper's title and publication details.

Phase II trial evaluates ponatinib for metastatic gastrointestinal stromal tumor, indicating potential effectiveness in T670I-mutant KIT patients.

Structural Analyses of sunitinib, regorafenib and ripretinib in T670I-mutant KIT

No takes yet. Share an insight, caveat, or question.

Falkenhorst et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share